share_log

科濟藥業-B:截至2024年3月31日止月份之股份發行人的證券變動月報表

CARSGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

香港交易所 ·  Apr 8 18:53
Summary by Futu AI
科濟藥業-B(02171.HK)於2024年4月8日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年3月31日的公司股份變動情況。報告顯示,公司的法定/註冊股本結存維持不變,為200,000,000,000股,每股面值0.00000025美元,總額為50,000美元。此外,根據2019年股權激勵計劃和首次公開發售後購股權計劃,公司於本月內無新增股份發行,但有225,481股份期權失效。截至報告期末,根據2019年股權激勵計劃可能發行的新股份數量為3,798,492股。公司確認,所有本月發行的證券均已獲得董事會授權,並符合香港聯合交易所有限公司證券上市規則的相關要求。
科濟藥業-B(02171.HK)於2024年4月8日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年3月31日的公司股份變動情況。報告顯示,公司的法定/註冊股本結存維持不變,為200,000,000,000股,每股面值0.00000025美元,總額為50,000美元。此外,根據2019年股權激勵計劃和首次公開發售後購股權計劃,公司於本月內無新增股份發行,但有225,481股份期權失效。截至報告期末,根據2019年股權激勵計劃可能發行的新股份數量為3,798,492股。公司確認,所有本月發行的證券均已獲得董事會授權,並符合香港聯合交易所有限公司證券上市規則的相關要求。
KOCHI PHARMACEUTICAL-B (02171.HK) FILED ITS LATEST SECURITIES CHANGE MONTH REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 8, 2024, REPORTING THE CHANGES IN COMPANY SHARES FOR THE YEAR ENDED MARCH 31, 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL WAS UNCHANGED AT 200,000,000,000 SHARES WITH A FACE VALUE OF $0.000025 PER SHARE FOR A TOTAL OF $50,000. In addition, under the 2019 Stock Incentive Program and the Initial Public Offering Post-IPO Share Option Plan, the Company issued no additional shares during the month, but 225,481 share options expired. As of the end of the reporting period, the number of new shares that may be issued under the Equity Incentive Scheme in 2019 is 3,798,492 shares. The Company confirms that all securities issued this month have been authorized by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
KOCHI PHARMACEUTICAL-B (02171.HK) FILED ITS LATEST SECURITIES CHANGE MONTH REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 8, 2024, REPORTING THE CHANGES IN COMPANY SHARES FOR THE YEAR ENDED MARCH 31, 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL WAS UNCHANGED AT 200,000,000,000 SHARES WITH A FACE VALUE OF $0.000025 PER SHARE FOR A TOTAL OF $50,000. In addition, under the 2019 Stock Incentive Program and the Initial Public Offering Post-IPO Share Option Plan, the Company issued no additional shares during the month, but 225,481 share options expired. As of the end of the reporting period, the number of new shares that may be issued under the Equity Incentive Scheme in 2019 is 3,798,492 shares. The Company confirms that all securities issued this month have been authorized by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.